Monthly Archives: April 2012

Uncertain Outlook for Pharma and Biotech Deals Following 'Turbulent' 2011

Peter Young, President and Managing Director of international investment bank Young & Partners, looks at what lies ahead for pharma and biotech following a turbulent 2011. The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will […]
Posted in Global, Guest Blog, leadership, Strategy | Tagged , , , , , | Leave a comment

Supreme Court to Consider Sales Rep Overtime

Posted in compliance, Legal, Marketing, People, Podcasts, Sales, Strategy | Leave a comment

Trust Issues: Dealing with Academia

Worried they might get taken for a ride, university tech transfer offices are beginning to hire ex-pharma and biotech personnel to help negotiate deals with industry. On exiting a theater, writers are often astounded and dismayed by the film resulting from a screenplay they’ve sold to a producer. Punch-up writers have added corny jokes, directors […]
Posted in Biotech, Deals, IP, leadership, R&D, Strategy, Technology | Tagged , , , , | 1 Comment

Supreme Court Considers the Affordable Care Act

Posted in Corporate Responsibility, healthcare, Legal, Regulatory, Strategy | Tagged , , , , , , , , | Leave a comment

Join the Adherence Conversation

Medication adherence is an ongoing and serious problem; according to the Center for Health Transformation, the annual cost of patients not taking their medicines as prescribed is nearly $300 billion, with approximately 125,000 patients dying each year due to poor adherence—that’s 342 people every day. Improving adherence rates in the United States has been a […]
Posted in Events | Tagged , | Leave a comment
  • Categories

  • Meta